Channel Therapeutics Corporation Announces Name Change Reflecting Focus on Non-Opioid Pain Therapeutics
Channel Therapeutics Corporation Announces Name Change Reflecting Focus on Non-Opioid Pain Therapeutics
The name change reflects the company's focus on sodium channel modulation and blockade for pain treatment.Channel Therapeutics rebrands to focus on sodium channel-based pain treatments, anticipating key efficacy data soon.
Channel Therapeutics重新品牌以专注于基于钠通道的疼痛治疗，并预计很快会有关键的疗效数据。
Quiver AI Summary
Quiver AI 概要
Chromocell Therapeutics Corporation has officially changed its name to Channel Therapeutics Corporation as of November 18, 2024, to better represent its focus on developing non-opioid pain treatments through sodium channel modulation, specifically targeting the NaV1.7 ion channel. The company has also reincorporated in Nevada to benefit from lower tax rates and increased flexibility in strategic and licensing efforts. CEO Frank Knuettel II expressed optimism about upcoming efficacy results from their eye pain and depot programs, viewing them as significant milestones for the company's growth. Current efficacy studies for these programs are ongoing, with results expected soon, while plans for Phase II human trials are anticipated to start in Q2 2025. Channel Therapeutics aims to address various types of pain, including chronic and postoperative pain, through innovative non-addictive therapies.
Chromocell Therapeutics Corporation已于2024年11月18日正式更名为Channel Therapeutics Corporation，以更好地代表其通过钠通道调节开发非阿片类疼痛治疗的重点，特别是针对NaV1.7离子通道。该公司还在内华达州重新注册，以受益于更低的税率和在战略及许可方面的更大灵活性。首席执行官Frank Knuettel II对即将公布的眼部疼痛和注射药物项目的疗效结果表示乐观，认为这是公司增长的重大里程碑。这些项目的当前疗效研究正在进行中，预计结果很快会出来，而第二阶段人体试验的计划预计将在2025年第二季度开始。Channel Therapeutics旨在通过创新的非成瘾疗法解决各种类型的疼痛，包括慢性和术后疼痛。
Potential Positives
潜在的积极因素
- The name change to Channel Therapeutics reflects a clear focus on sodium channel modulation, potentially enhancing clarity in the company's branding and mission.
- The company expects significant near-term data readouts from their eye pain and depot programs, which could result in important milestones for growth and valuation.
- Reincorporating in Nevada is anticipated to lead to lower tax rates and increased flexibility in strategic and licensing pursuits, potentially benefiting the company's financial position.
- The imminent results from ongoing efficacy studies could elevate investor confidence and interest in the company's non-opioid pain therapeutics developments.
- 更名为Channel Therapeutics反映出明确关注钠通道调节，有可能增强公司品牌和使命的清晰度。
- 公司预计其眼部疼痛和注射药物项目将在短期内发布重要数据，这可能导致增长和估值的重要里程碑。
- 在内华达州重新注册预计将导致更低的税率和在战略及许可追求中的更大灵活性，可能会对公司的财务状况产生积极影响。
- 即将发布的疗效研究结果可能会提高投资者对该公司非阿片类疼痛治疗开发的信心和兴趣。
Potential Negatives
潜在负面影响
- The name change to Channel Therapeutics may indicate a perceived need for rebranding, which could suggest an previous identity or focus did not resonate well with stakeholders.
- The press release heavily relies on forward-looking statements, introducing uncertainty about future performance and outcomes related to the Company's clinical programs.
- The mention of exploring program-specific financing for their chronic pain program may indicate potential funding challenges or a lack of guaranteed financial support for that area of research.
- 更名为Channel Therapeutics可能表明对重新品牌化的迫切需求，这可能暗示之前的身份或重点未能与利益相关者产生良好共鸣。
- 新闻稿很大程度上依赖于前瞻性声明，这引入了关于公司临床项目未来表现和结果的不确定性。
- 提到为其慢性疼痛项目探索特定资金的可能性，可能表明在该研究领域面临潜在的融资挑战或缺乏有保障的财务支持。
FAQ
FAQ
What is the new name of Chromocell Therapeutics Corporation?
Chromocell Therapeutics Corporation的新名称是什么？
The company has changed its name to Channel Therapeutics Corporation.
公司已更名为Channel Therapeutics Corporation。
Why did the company change its name?
公司为何更改名称？
The name change reflects the company's focus on sodium channel modulation and blockade for pain treatment.
名称的更改反映了公司在疼痛治疗方面对钠通道调节和封锁的关注。
What are the key therapeutic programs being developed?
正在开发的关键治疗项目有哪些？
Key programs include the Depot Program for postoperative nerve blocks and an eye pain program.
关键项目包括用于术后神经阻滞的Depot项目和眼部疼痛项目。
When does Channel Therapeutics expect to start human trials?
Channel Therapeutics 预计什么时候开始人体试验？
Channel Therapeutics anticipates commencing Phase II human studies in Q2 2025.
Channel Therapeutics 预计在2025年第二季度开始进行二期人体研究。
What benefits will reincorporating in Nevada provide the company?
在内华达州重新注册将为公司带来什么好处？
The company expects lower tax rates and greater flexibility for strategic and licensing pursuits.
公司预计税率将降低，并在战略和许可追求方面具有更大的灵活性。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$CHRO Insider Trading Activity
$CHRO内部交易活动
$CHRO insiders have traded $CHRO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
$CHRO内部人士在过去6个月内已在公开市场上交易了$CHRO股票5次。在这些交易中，5次是购买，0次是销售。
Here's a breakdown of recent trading of $CHRO stock by insiders over the last 6 months:
以下是$CHRO股票在过去6个月内内部人士近期交易的详细信息：
- KNUETTEL II FRANCIS (CEO, Pres., CFO, Treas & Secty) has traded it 4 times. They made 4 purchases, buying 17,200 shares and 0 sales.
- RICHARD MALAMUT purchased 10,400 shares.
- KNUETTEL II FRANCIS（首席执行官，总裁，首席财务官，财政及秘书）交易了4次。他们进行了4次购买，购买了17,200股，0次销售。
- RICHARD MALAMUt 购买了10,400股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟踪内部交易，请查看Quiver Quantitative的内部交易特斯拉-仪表。
$CHRO Hedge Fund Activity
$CHRO对冲基金活动
We have seen 5 institutional investors add shares of $CHRO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
我们看到5家机构投资者在最近的季度中增加了$CHRO股票的持有，3家减少了其持仓。
Here are some of the largest recent moves:
以下是一些最近最大的交易动态：
- ANSON FUNDS MANAGEMENT LP removed 201,030 shares (-100.0%) from their portfolio in Q3 2024
- AVANTAX PLANNING PARTNERS, INC. added 47,205 shares (+inf%) to their portfolio in Q3 2024
- TWO SIGMA SECURITIES, LLC added 26,061 shares (+inf%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 18,714 shares (-100.0%) from their portfolio in Q3 2024
- WEALTH ENHANCEMENT ADVISORY SERVICES, LLC added 10,400 shares (+inf%) to their portfolio in Q3 2024
- TOWER RESEARCH CAPITAL LLC (TRC) added 253 shares (+4216.7%) to their portfolio in Q3 2024
- UBS GROUP AG removed 186 shares (-100.0%) from their portfolio in Q3 2024
- 安森基金管理LP在2024年第三季度从他们的投资组合中移除了201,030股（-100.0%）
- Avantax规划合作伙伴公司在2024年第三季度向他们的投资组合中增加了47,205股（+inf%）
- Two Sigma证券公司在2024年第三季度向他们的投资组合中增加了26,061股（+inf%）
- 城堡顾问公司在2024年第三季度从他们的投资组合中移除了18,714股（-100.0%）
- 财富提升咨询服务公司在2024年第三季度向他们的投资组合中增加了10,400股（+inf%）
- 塔架研究资本公司在2024年第三季度向他们的投资组合中增加了253股（+4216.7%）
- 瑞银集团在2024年第三季度从他们的投资组合中移除了186股（-100.0%）
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追踪对冲基金的股票组合，请查看Quiver Quantitative的机构持股仪表板。
Full Release
全面发布
-
"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulation
-
New name is in advance of multiple near-term data readouts
-
"通道治疗" 反映了公司专注于开发利用钠通道阻滞和调节治疗疼痛的治疗方法。
-
新名称之前有多个近期数据公布
FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation ("Channel" or the "Company"), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for the treatment of pain.
新泽西州，FREEHOLD，2024年11月21日（全球新闻社）— Chromocell Therapeutics Corporation（纽约证券交易所美国：CHRO），作为非阿片类疼痛治疗药物开发的先驱，今天宣布，于2024年11月18日更名为Channel Therapeutics Corporation（"Channel" 或 "公司"），并重新在内华达州注册成立。 公司认为更名更好地反映了其基于钠通道调节和阻塞开发疼痛治疗方法的专注。
"The specific sodium channel we are targeting, NaV1.7, is the most genetically validated of the different sodium channels and we have demonstrated efficacy in a broad array of animal models. We believe the name change better reflects our multi-pronged approach towards targeting pain reduction, said Frank Knuettel II, CEO of Channel.
"我们正在瞄准的特定钠通道NaV1.7，在不同的钠通道中具有最具遗传验证性，并且我们已经在广泛的动物模型中展示了疗效。 我们相信更名更好地反映了我们针对减轻疼痛的多管齐下方法，"Channel"的首席执行官Frank Knuettel II表示。
"Additionally, our team continues to make progress across our multiple non-opioid based pain therapeutic programs, and we eagerly look forward to sharing the efficacy results for both of the eye pain and depot programs as they could be important milestones in Channel Therapeutics' growth and valuation," concluded Knuettel.
"此外，我们的团队在继续推进我们的多个非阿片类疼痛治疗项目的同时，我们急切期待着分享关于眼痛和缓释项目的疗效结果，因为它们可能是"Channel Therapeutics"增长和估值中的重要里程碑，"Knuettel补充道。
Commensurate with the change in the Company's new name, Channel has also reincorporated in the State of Nevada, by way of a merger into a wholly owned Nevada subsidiary. The Company expects to experience lower tax rates and more flexibility in its strategic and licensing pursuits.
随着公司新名称的更改，Channel也通过与美国内华达州全资子公司合并的方式进行再注册。公司预计将享受更低的税率，并在战略和许可追求方面拥有更多灵活度。
Therapeutic Program Update:
治疗计划更新：
-
Depot Program for Postoperative Nerve Blocks
– the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently.
-
Eye Pain Program
– the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late Q1 2025. The Company expects to commence Phase II human proof of concept studies in Q2 2025, with a readout by the end of 2025.
-
Chronic Pain
– the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in Q1 2025.
-
术后神经阻滞装置计划
– 公司在动物实验中显示出持续释放药物的效果，持续时间达96小时，目前正在进行动物有效性研究，结果预计即将公布。
-
眼疼痛方案
– 在一项动物研究中，眼药水被良好耐受，且公司正在进行眼痛动物模型的有效性研究，毒理学研究将很快开始。有效性研究的结果预计在接下来的几周内公布，毒理学数据预计在2025年第一季度末公布。公司预计将在2025年第二季度开始进行第二阶段的人员概念验证研究，预计在2025年底之前完成结果分析。
-
慢性疼痛
– 公司正在探索这个项目的特定融资，预计该项目将在2025年第一季度启动。
About Channel
关于频道
Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit
or follow us on social media.
Channel Therapeutics Corporation是一家临床阶段的生物技术公司，专注于开发和商业化新型非阿片类、非成瘾性的治疗药物，以缓解疼痛。公司的初步临床重点是选择性靶向被称为NaV1.7的钠离子通道，以治疗各种类型的慢性疼痛、急性和慢性眼部疼痛以及术后神经阻滞。有关公司的最新动态以及了解更多关于Channel的信息，请访问
或在社交媒体上关注我们。
Forward-Looking Statements
前瞻性声明
This press release contains forward-looking statements regarding the Company's current expectations. These forward-looking statements include, without limitation, references to the Company's expectations regarding (i) the Company's belief that its name change better reflects the Company's focus on developing therapeutics based on sodium channel modulation and blockade for the treatment of pain and therefore its multi-pronged approach towards targeting pain reduction, (ii) the Company's belief that the efficacy results for the Company's eye pain and depot programs could be important milestones in the Company's growth and valuation, and (iii) the Company's ability to experience lower tax rates and more flexibility in its strategic and licensing pursuits as a result of reincorporating in the State of Nevada. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company's Common Stock will be indicative of the Company's value or that the Company's Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
本新闻稿包含关于公司当前期望的前瞻性声明。这些前瞻性声明包括但不限于关于公司期望的参考，(i) 公司相信其更名更好地反映了公司专注于基于钠通道调节和阻滞开发治疗疼痛的疗法，因此采取了多管齐下的途径进行疼痛缓解的目标，(ii) 公司认为公司眼部疼痛和药库项目的功效结果可能是公司成长和估值的重要里程碑，以及 (iii) 公司重新设立在内华达州的公司法人地位有助于公司享受较低的税率和在战略和许可方面拥有更多灵活性。这些声明不构成未来业绩的保证，而是受难以预测的某些风险、不确定性和假设的影响。可能导致实际结果与此类前瞻性声明不同的因素包括但不限于与公司普通股交易价格是否能反映公司价值或公司普通股是否将来成为有吸引力的投资并无明确保证的风险和不确定性。这些以及其他风险和不确定性在我们向美国证券交易委员会提交的文件中有更详细的描述。本新闻稿中的信息仅截至本新闻稿日期提供，除非法律要求，我们不承诺根据新信息、将来事件或其他原因更新本新闻稿中包含的任何前瞻性声明。
Channel Media and Investor Inquires:
媒体和投资者查询：
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
投资者查询：
迈克·莫迪尔
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
